Latest Breaking News On - Clarus therapeutics inc - Page 6 : comparemela.com

Clarus Therapeutics Defeats Lipocine s Patent Infringement Lawsuit On Summary Judgment US District Court for the District of Delaware grants Clarus s Motion for Summary Judgment against remaining patents in patent infringement case brought by Lipocine, Inc. regarding Clarus s oral testosterone replacement product JATENZO® News provided by Share this article Share this article NORTHBROOK, Ill., May 25, 2021 /PRNewswire/  Today, Federal Circuit Judge William C. Bryson, a Senior Circuit Judge of the U.S. Court of Appeals for the Federal Circuit, sitting by designation in the U.S. District Court for the District of Delaware, granted Clarus s motion for summary judgment against Lipocine, Inc. ( Lipocine ;NASDAQ: LPCN) for failure to provide adequate written description of Lipocine s asserted patent claims.  In his decision, which gives Clarus an unequivocal win, Judge Bryson found all of the asserted Lipocine patent claims invalid.  Clarus s defense of inequitable conduct, to be

New yorkUnited statesWilliamc brysonDavid schullRobert dudleyUs courtLipocine incUs district courtClarus therapeutics incFederal circuit judge williamSenior circuit judgeFederal circuitJudge brysonClarus therapeuticsBlue waterClarus therapeutic